pirenzepine has been researched along with Exocrine Pancreatic Insufficiency in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Exocrine Pancreatic Insufficiency: A malabsorption condition resulting from greater than 10% reduction in the secretion of pancreatic digestive enzymes (LIPASE; PROTEASES; and AMYLASE) by the EXOCRINE PANCREAS into the DUODENUM. This condition is often associated with CYSTIC FIBROSIS and with chronic PANCREATITIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| von Kleist, D | 1 |
| Rössler, W | 1 |
| Janisch, HD | 1 |
| Hampel, KE | 1 |
1 trial available for pirenzepine and Exocrine Pancreatic Insufficiency
| Article | Year |
|---|---|
[The diagnostic value of serum PABA determination in pancreatic disease and in relation to anticholinergic medication].
Topics: 4-Aminobenzoic Acid; Adult; Cholecystokinin; Dose-Response Relationship, Drug; Exocrine Pancreatic I | 1989 |